CAN1012 in Pre-malignant Oral Dysplasia

Starting soon · Phase 1

Conditions studied: Oral Epithelial Dysplasia (OED)

In brief

The primary objective of this trial is to examine the safety of CAN1012 delivered by intralesional injection ahead of planned surgical resection.

Key facts

Study ID

NCT07620496

Run by

Providence Health & Services

People needed

36

Starts

2026-07-01

Expected to finish

2033-07-01

Last updated by the study team

2026-06-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinically-identified oral epithelial dysplasia (OED)
• Age 18 years or above with ability to give informed consent, comply with the protocol, and sign a study-specific consent document.
• Eastern Cooperative Oncology Group (ECOG) performance status 0-1 deemed suitable by investigator or designee for requirements of study.
• Laboratory values within 72 hours of Day 0:
• WBC ≥ 2.0 K/µL, ANC ≥ 1.0 K/µL
• Hgb ≥ 10 g/dL
• Platelets ≥ 100,000 K/µL
• Creatinine Clearance (using Cockcroft-Gault)
• AST/ALT ≤ 2.5 x ULN
• Total bilirubin ≤ 3 x ULN, (except subjects with Gilbert's Syndrome, who must have a total bilirubin less than 3.0 mg/dL)
• Negative pregnancy test (bHCG urine or serum, people of childbearing potential only)
• Patients and their partners who are capable of conceiving must agree to use effective methods of during the course of treatment and for 165 days after last dose of CAN1012.

You may not qualify if…

• Any serious underlying medical or psychiatric condition that, in the opinion of the investigator, would pose a risk to patient safety or interfere with the study procedures, completion, or evaluation.
• Need for corticosteroids ≥ 10mg prednisone daily equivalent; inhaled steroids are acceptable.
• Need for hormonal contraception including oral contraceptives, implant, injectable depots, vaginal rings, skin patches, and the progestin IUD; or any medication that is a sensitive substrate of the major CYPs.
• History of or current active autoimmune diseases which, in the judgment of the investigator, pose an active and significant risk. Vitiligo, lichen planus or lichenoid inflammation, and adequately controlled endocrine deficiencies such as hypothyroidism/ hyperthyroidism are not exclusionary.
• Previous history of bone marrow transplantation or oral Graft Versus Host Disease (GVHD).
• Has an active infection requiring systemic therapy. Investigator may allow if deemed not clinically significant.
• Has active or uncontrolled Hepatitis B, Hepatitis C, or HIV with AIDS (acquired immunodeficiency syndrome)- defined opportunistic infection.
• Has a baseline electrocardiogram (ECG) with a prolonged QTc interval > 480 msec. Medications which have a known and clinically significant risk of QT prolongation may be allowed per investigator discretion.
• Patients who have had a history of acute diverticulitis, intra-abdominal abscess, GI obstruction and abdominal carcinomatosis which are known risk factors for bowel perforation, and in the judgment of the investigator still pose an active risk.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.